PMID- 2145750
OWN - NLM
STAT- MEDLINE
DCOM- 19901120
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 66
IP  - 13
DP  - 1990 Oct 16
TI  - Comparison of SPECT using technetium-99m agents and thallium-201 and PET for the 
      assessment of myocardial perfusion and viability.
PG  - 72E-79E
AB  - This report reviews the applications of tomographic imaging with current and new 
      tracers in assessing myocardial perfusion and viability. Multiple studies with 
      thallium-201 (TI-201) single photon emission computed tomography (SPECT) imaging 
      for the detection of coronary artery disease (CAD) have demonstrated high 
      sensitivity, high rates of normalcy and high reproducibility. In assessing 
      viability, fixed defects are frequently detected in viable zones in 4-hour 
      studies with TI-201 imaging. Redistribution imaging performed 18 to 72 hours 
      after injection or reinjection of TI-201 before 4-hour redistribution imaging has 
      been shown to improve accuracy of viability assessment. TI-201 SPECT studies are 
      limited by the suboptimal physical properties of TI-201, which result in variable 
      image quality. The 2 new technetium-99m (Tc-99m) - labeled myocardial perfusion 
      tracers offer the ability to inject much higher amounts of radioactivity, making 
      it possible to assess ventricular function as well as myocardial perfusion from 
      the same injection of radiotracer. Tc-99m sestamibi has very slow myocardial 
      clearance, which allows for prolonged imaging time and results in image quality 
      superior to that obtained with TI-201 and Tc-99m teboroxime. The combination of 
      minimal redistribution of Tc-99m sestamibi and high count rates makes gated SPECT 
      imaging feasible, and also permits assessment of patients with acute ischemic 
      syndromes by uncoupling the time of injection from the time of imaging. The 
      combination of high image quality and first-pass exercise capabilities may lead 
      to a choice of this agent over TI-201 for assessment of chronic CAD.(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Berman, D S
AU  - Berman DS
AD  - Department of Medicine (Division of Cardiology) Cedars-Sinai Medical Center, Los 
      Angeles California 90048.
FAU - Kiat, H
AU  - Kiat H
FAU - Van Train, K F
AU  - Van Train KF
FAU - Friedman, J
AU  - Friedman J
FAU - Garcia, E V
AU  - Garcia EV
FAU - Maddahi, J
AU  - Maddahi J
LA  - eng
GR  - 7651/PHS HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Fluorine Radioisotopes)
RN  - 0 (Nitriles)
RN  - 0 (Organotechnetium Compounds)
RN  - 0 (Oximes)
RN  - 0 (Thallium Radioisotopes)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 971Z4W1S09 (Technetium Tc 99m Sestamibi)
RN  - 9G2MP84A8W (Deoxyglucose)
RN  - UT0WHJ4951 (technetium Tc 99m teboroxime)
SB  - IM
MH  - Coronary Disease/*diagnostic imaging
MH  - Deoxyglucose/analogs & derivatives
MH  - Fluorine Radioisotopes
MH  - Fluorodeoxyglucose F18
MH  - Heart/diagnostic imaging
MH  - Humans
MH  - Meta-Analysis as Topic
MH  - *Nitriles
MH  - *Organotechnetium Compounds
MH  - *Oximes
MH  - Sensitivity and Specificity
MH  - Technetium Tc 99m Sestamibi
MH  - *Thallium Radioisotopes
MH  - *Tomography, Emission-Computed
MH  - *Tomography, Emission-Computed, Single-Photon
EDAT- 1990/10/16 00:00
MHDA- 1990/10/16 00:01
CRDT- 1990/10/16 00:00
PHST- 1990/10/16 00:00 [pubmed]
PHST- 1990/10/16 00:01 [medline]
PHST- 1990/10/16 00:00 [entrez]
AID - 0002-9149(90)90616-9 [pii]
AID - 10.1016/0002-9149(90)90616-9 [doi]
PST - ppublish
SO  - Am J Cardiol. 1990 Oct 16;66(13):72E-79E. doi: 10.1016/0002-9149(90)90616-9.